

IFW



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 10/5/04 Signature: Crena Pacheco
(Crena Pacheco)

Docket No.: YU-P01-024
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Mor et al.

Application No.: 10/779360

Confirmation No.: 7903

Filed: February 13, 2004

Art Unit: 1651

For: IN VITRO TEST TO DETECT RISK OF
PREECLAMPSIA

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this

application by this firm) to our Deposit Account No. 18-1945, under Order No. YU-P01-024.

Dated: October 5, 2004

Respectfully submitted,

By Patricia Granahan
Patricia Granahan

Registration No.: 32,227

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



PTO/SB/21 (04-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/779360
		Filing Date	February 13, 2004
		First Named Inventor	Guillermo Mor
		Art Unit	1651
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	7	Attorney Docket Number	YU-P01-024

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): IDS Form SB/08 (3 pages) References (CA-CN1) (40) Return Receipt Postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	ROPES & GRAY LLP Patricia Granahan. - 32,227
Signature	<i>Patricia Granahan</i>
Date	October 5, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 10-5-04 Signature: Crena Pacheco (Crena Pacheco)



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/779360
				Filing Date	February 13, 2004
				First Named Inventor	Guillermo Mor
				Art Unit	1651
				Examiner Name	Not Yet Assigned
Sheet	1	of	4	Attorney Docket Number	YU-P01-024

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	Khong, T.Y., et al., "Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small-for-gestational age infants," Br J Obstet Gynaecol, 93: 1049-59 (1986).		
	CB	Zhou, Y., et al., "Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?", J Clin Invest, 99: 2152-64 (1997).		
	CC	Fisher, S.J., "The placenta dilemma," Semin Reprod Med, 18: 321-6 (2000).		
	CD	DeWolf, F., et al., "Ultrastructure of the spiral arteries in the human placental bed at the end of normal pregnancy," Am J Obstet Gynecol, 117: 833-48 (1973).		
	CE	Buemi, M., et al., "Is apoptosis cause of preeclampsia?", Eur Rev Med Pharmacol Sci, 2: 185-8 (1998).		
	CF	Levy, R., et al., "To be, or not to be, that is the question. Apoptosis in human trophoblast" Placenta, 21: 1-13 (2000).		
	CG	Mor, G., et al., "Role of the Fas/Fas ligand system in female reproductive organs: survival and apoptosis," Biochem Pharmacol, 64: 1305 (2002).		
	CH	Straszewski, S.L., et al., "Confers Human Trophoblast Cell Resistance to Fas-Mediated Apoptosis," Molecular Human Reproduction (2004) in press.		
	CI	Smith, S.C., et al., "Increased placental apoptosis in intrauterine growth restriction," Am J Obstet Gynecol, 177: 1395-401 (1997).		
	CJ	Levy, R., et al., "Trophoblast apoptosis from pregnancies complicated by fetal growth restriction is associated with enhanced p53 expression," Am J Obstet Gynecol, 186: 1056-61 (2002).		
	CK	Smith, S.C., et al., "Placental apoptosis in normal human pregnancy," Am J Obstet Gynecol, 177: 57-65 (1997).		
	CL	Aschkenazi, S., et al., "Differential regulation and function of the fas/fas ligand system in human trophoblast cells," Biol Reprod, 66: 1853-61 (2002).		
	CM	Chua, S., et al., "Trophoblast deportation in pre-eclamptic pregnancy," Br J Obstet Gynaecol, 98: 973-9 (1991).		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
				Application Number	10/779360
				Filing Date	February 13, 2004
				First Named Inventor	Guillermo Mor
				Art Unit	1651
				Examiner Name	Not Yet Assigned
Sheet	2	of	4	Attorney Docket Number	YU-P01-024

CN	Johansen, M., et al., "Trophoblast deportation in human pregnancy--its relevance for preeclampsia," Placenta, 20: 531-9 (1999).
CO	Sargent, I.L., et al., "Clinical experience: isolating trophoblasts from maternal blood," Ann N Y Acad Sci., 731: 154-61 (1994).
CP	Knight, M., et al., "Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies," Br J Obstet Gynaecol, 105: 632-40 (1998).
CQ	Kertesz, Z., et al., "Purification and characterization of a complex from placental syncytiotrophoblast microvillous membranes which inhibits the proliferation of human umbilical vein endothelial cells," Placenta, 20: 71-9 (1999).
CR	Mor, G., et al., "Fas-Fas ligand system induced apoptosis in human placenta and gestational trophoblastic disease," American Journal of Reproductive Immunology, 40: 89-95 (1998).
CS	Athayde, N., et al., "Interleukin 16 in pregnancy, parturition, rupture of fetal membranes, and microbial invasion of the amniotic cavity," Am J Obstet Gynecol, 182: 135-41 (2000).
CT	Romero, R., et al., "Further observations on the fetal inflammatory response syndrome: a potential homeostatic role for the soluble receptors of tumor necrosis factor alpha," Am J Obstet Gynecol, 183: 1070-7 (2000).
CU	Rudin, C.M., et al., "Apoptosis and disease: regulation and clinical relevance of programmed cell death," Annu Rev Med, 48: 267-81 (1997).
CV	DiFederico, E., et al., "Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall," Am J Pathol, 155: 293-301 (1999).
CW	DeWolf, F., et al., "The ultrastructure of acute atherosclerosis in hypertensive pregnancy," Am J Obstet Gynecol, 123: 164-74 (1975).
CX	Roberts, JM, "Preeclampsia: What We Know and What We Do Not Know," Semin Perinatol 24: 24-8 (2000).
CY	The Magpie Trial Collaborative Group, "Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomized placebo-controlled trial," Lancet 359: 1877-90 (2002).
CZ	Williams, J.W., "Premature separation of the Normally Implanted Placenta," Surg Gynecol Obstet 21(5): 541-554 (1915).
CA1	Chesley, L.C., "The Control of Hypertension in Pregnancy," Obstet Gynecol Annu 10: 69-106 (1981).
CB1	Tatum, H.J. and Mule J.G., The hypertensive action of blood from patients with pre-eclampsia," Am J Obstet Gynecol 83: 1028-35 (1962).
CC1	Tatum, H.J., "The Obstetric Patient with Toxemia," Clin Obstet Gynecol 13: 233-48 (1964).
CD1	Pirani, B.B. and MacGillivray, I., "The effect of plasma retransfusion on blood pressure in the puerperium," AM J Obstet Gynecol 121: 221-6 (1975).
CE1	Gant, N.F., et al., "The Nature of Pressor Responsiveness to Angiotensin II in Human Pregnancy," Obstet Gynecol 43(6): 854 (1974).
CF1	Gant, N.F., et al., "A Study of Angiotensin II Pressor Response throughout Primigravid Pregnancy," J Clin Invest 52: 2682-9 (1973).
CG1	Zuspan, F.P., "Catecholamines: Their Role in Pregnancy and the Development of Pregnancy-Induced Hypertension," J Reprod Med 23(3): 143-50 (1979).
CH1	Zuspan, F.P., "Urinary amine alterations in drug-addiction pregnancy," Am J Obstet Gynecol 126(7): 955-64 (1976).
CI1	Krege, J.H. and Katz, V.L., "A Proposed Relationship Between Vasopressinase Altered Vasopressin and Preeclampsia," Med Hypotheses 31: 283-7 (1990).
CJ1	McKinney, E.T., et al., "Plasma, urinary, and salivary 8-epi-prostaglandin f _{2a} levels in normotensive and preeclamptic pregnancies," Am J Obstet Gynecol 183(4): 874-7 (2000).
CK1	Clark, B.A., et al., "Plasma endothelin levels in preeclampsia: Elevation and correlation with uric acid levels and renal impairment," Am J Obstet Gynecol 166(3): 962-8 (1992).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/779360
				Filing Date	February 13, 2004
				First Named Inventor	Guillermo Mor
				Art Unit	1651
				Examiner Name	Not Yet Assigned
Sheet	3	of	4	Attorney Docket Number	YU-P01-024

	CL1	Pedersen, E.B., et al., "Renin, Angiotensin II, Aldosterone, Catecholamines, Prostaglandins and Vasopressin. The Importance of Pressor and Depressor Factors for Hypertension in Pregnancy," Scand J Clin Lab Invest Suppl 169: 48-56 (1984).	
	CM1	Aalkjaer, C., et al., "Morphology and Angiotensin II Responsiveness of Isolated Resistance Vessels from Patients with Pre-eclampsia," Scand J Clin Lab Invest Suppl 169: 57-60 (1984).	
	CN1	Neale, D., et al., "Maternal serum of women with pre-eclampsia reduces trophoblast cell viability: evidence for an increased sensitivity to Fas-mediated apoptosis," J Matern Fetal Neonatal Med 13: 39-44 (2003).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--